 "Vials, Vaccine")
Gennova Biopharmaceuticals, a subsidiary of Pune-headquartered Emcure Pharmaceuticals, is not only developing India’s first indigenous messenger ribonucleic acid (mRNA) Covid-19 vaccine, but also plans to leverage the platform to develop vaccines for the Zika virus, herpes zoster (shingles), and tuberculosis (TB).
“The mRNA platform is disease-agnostic. We had started work on this a few years back when we collaborated with Seattle-based HDT Biotech Corporation for developing a therapeutic vaccine for cancer (human papillomavirus-induced cervical cancer in women),” said Samit Mehta, president and chief operating officer, Gennova. He added that the company planned to use the platform to make vaccines
“The mRNA platform is disease-agnostic. We had started work on this a few years back when we collaborated with Seattle-based HDT Biotech Corporation for developing a therapeutic vaccine for cancer (human papillomavirus-induced cervical cancer in women),” said Samit Mehta, president and chief operating officer, Gennova. He added that the company planned to use the platform to make vaccines
